Abciximab (ReoPro)-Induced Thrombocytopenia Diagnosed Through Measurement of Heparin-Dependent Antibody
Korean Circulation Journal
; : 75-78, 2009.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-161235
Responsible library:
WPRO
ABSTRACT
Abciximab (ReoPro) is an extremely potent inhibitor of the glycoprotein IIb/IIIa receptor. Its main application is in the maintenance of coronary flow after suboptimal coronary intervention. Complications associated with this drug include bleeding and severe thrombocytopenia. We report a case of severe thrombocytopenia secondary to abciximab therapy for percutaneous coronary intervention in a 65-year-old woman suffering from an acute myocardial infarction. Her platelet count dropped to 1,000/mm3 7 hours after abciximab administration and improved with transfusion of 12 units of platelet concentrate the following day. The patient was diagnosed through measurement of heparin-dependent antibodies and readministration of heparin.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Platelet Count
/
Stress, Psychological
/
Thrombocytopenia
/
Blood Platelets
/
Immunoglobulin Fab Fragments
/
Glycoproteins
/
Heparin
/
Percutaneous Coronary Intervention
/
Hemorrhage
/
Antibodies
Type of study:
Diagnostic study
Limits:
Aged
/
Female
/
Humans
Language:
English
Journal:
Korean Circulation Journal
Year:
2009
Document type:
Article